Breaking Finance News

A statement released earlier today by Stifel about Spark Therapeutics (NASDAQ:ONCE) ups the target price to $101.00

In a report issued 10/13/2017 Stifel raised the target price of Spark Therapeutics (NASDAQ:ONCE) from $92.00 to $101.00 stating a potential upside of 0.17%.

On Thursday October 12, 2017, Raymond James released a statement on Spark Therapeutics (NASDAQ:ONCE) increased the target price from $0.00 to $96.00. At the time, this indicated a possible upside of 0.11%.

Yesterday Spark Therapeutics (NASDAQ:ONCE) traded 0.00% even at $86.20. ONCE’s 50-day average is $85.91 and its two hundred day average is $85.91. With the last stock price close up 0.34% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. Trade Volume was up over the average, with 536,939 shares of ONCE changing hands over the typical 447,313

See Chart Below

Spark Therapeutics (NASDAQ:ONCE)

With a total market value of $0, Spark Therapeutics has with a one year low of $35.07 and a one year high of $91.00 .

In addition to Stifel reporting its target price, a total of 9 firms have reported on Spark Therapeutics. The 12-month price target is $58.44 with zero equity analysts rating the company a strong buy, five equity analysts rating the company a buy, three brokerages rating the company a hold, zero analysts rating the company a underperform, and lastly one analyst rating the stock a sell.

General Information About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.